Pediatric research · 2026
The specifications of blood components for neonatal transfusion: a European study and critical review.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Houben Nina A M, Cardigan Rebecca, de Korte Dirk, Caram-Deelder Camila, Fazli Laila, Wikman Agneta, Larsson Stella, Radovčić Marko Karlo, Vinković Vlah Matea, Fustolo-Gunnink Suzanne, Roehr Charles C, Dame Christof, Stanworth Simon J, Lopriore Enrico, New Helen V, Neonatal Transfusion Network, SCONE collaborators
Аннотация
BACKGROUND: Blood component safety measures implemented by Blood Establishments (BE) specifically for neonates are frequently precautionary rather than evidence based. We conducted a European survey on specifications for neonatal red blood cells, platelet, and plasma transfusions.
METHODS: The survey was sent to transfusion experts in BEs in 38 European countries between May 2023 and January 2024. We received responses from 20/38 countries.
RESULTS: Many BEs provide neonatal components with additional safety features not routinely applied for adults, and we found evidence of significant variation in practice. 12/19 BEs used a shorter shelf life for split units compared to adult components. For neonatal exchange, 12/19 used saline-adenine-glucose-mannitol (SAGM) replaced with FFP prior to issue. Three BEs performed additional donor or component testing for neonatal units, including screening for lead concentrations (1/20).
CONCLUSION: We identified three questions for which we conducted a critical literature review, around use of short-shelf life of red cells, use of additive solutions, and significance of lead concentrations for neonatal components. Although there were relevant articles addressing these questions, we found a lack of definitive evidence for much precautionary practice, and a need for wider study of the impact of lead in neonatal transfusions to inform future strategies.
METHODS: The survey was sent to transfusion experts in BEs in 38 European countries between May 2023 and January 2024. We received responses from 20/38 countries.
RESULTS: Many BEs provide neonatal components with additional safety features not routinely applied for adults, and we found evidence of significant variation in practice. 12/19 BEs used a shorter shelf life for split units compared to adult components. For neonatal exchange, 12/19 used saline-adenine-glucose-mannitol (SAGM) replaced with FFP prior to issue. Three BEs performed additional donor or component testing for neonatal units, including screening for lead concentrations (1/20).
CONCLUSION: We identified three questions for which we conducted a critical literature review, around use of short-shelf life of red cells, use of additive solutions, and significance of lead concentrations for neonatal components. Although there were relevant articles addressing these questions, we found a lack of definitive evidence for much precautionary practice, and a need for wider study of the impact of lead in neonatal transfusions to inform future strategies.